• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Ambrx Biopharma Inc. (Amendment)

    6/28/23 4:45:12 PM ET
    $AMAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AMAM alert in real time by email
    SC 13D/A 1 p23-1852sc13da.htm AMBRX BIOPHARMA INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549
    _______________
     
    SCHEDULE 13D/A
     
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
    RULE 13d-2(a)
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
     
    Ambrx Biopharma Inc.
    (Name of Issuer)
     
    Ordinary Shares, without par value
    (Title of Class of Securities)
     
    02290A102**
    (CUSIP Number)
     

     

    Abhishek Trehan

    Darwin Global Management, Ltd.

    Whiteley Chambers, Don Street

    St. Helier, Y9 JE2 4TR

    +44 2045 264400

     

    with a copy to:

     

    Eleazer Klein, Esq.
    Adriana Schwartz, Esq.

    Schulte Roth & Zabel LLP

    919 Third Avenue

    New York, NY 10022

    (212) 756-2000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     
    June 27, 2023
    (Date of Event Which Requires Filing of This Statement)
     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. [x]

     

    (Page 1 of 8 Pages)

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     
     

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    **There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 02290A102 has been assigned to the American Depositary Shares ("ADSs") of the Issuer, which are quoted on the New York Stock Exchange under the symbol "AMAM." Each ADS represents 7 Ordinary Shares

     

     

    CUSIP No. 02290A102SCHEDULE 13DPage 3 of 8 Pages

     

    1

    NAME OF REPORTING PERSON

    Darwin Global Management, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) o

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Jersey

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    116,820,452 Ordinary Shares (represented by 16,688,636 ADSs)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    116,820,452 Ordinary Shares (represented by 16,688,636 ADSs)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    116,820,452 Ordinary Shares (represented by 16,688,636 ADSs)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    27.5%

    12

    TYPE OF REPORTING PERSON

    CO, IA

             

     

     

    CUSIP No. 02290A102SCHEDULE 13DPage 4 of 8 Pages

     

    1

    NAME OF REPORTING PERSON

    Dr. Abhishek Trehan

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) o

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Britain

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    116,820,452 Ordinary Shares (represented by 16,688,636 ADSs)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    116,820,452 Ordinary Shares (represented by 16,688,636 ADSs)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    116,820,452 Ordinary Shares (represented by 16,688,636 ADSs)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    27.5%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 02290A102SCHEDULE 13DPage 5 of 8 Pages

      

    1

    NAME OF REPORTING PERSON

    Darwin Global Master Fund, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) o

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    108,986,059 Ordinary Shares (represented by 15,569,437 ADSs)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    108,986,059 Ordinary Shares (represented by 15,569,437 ADSs)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    108,986,059 Ordinary Shares (represented by 15,569,437 ADSs)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    25.7%

    12

    TYPE OF REPORTING PERSON

    CO

             

     

     

    CUSIP No. 02290A102SCHEDULE 13DPage 6 of 8 Pages

     

    The following constitutes Amendment No. 2 to the Schedule 13D filed by the undersigned ("Amendment No. 2"). This Amendment No. 2 amends the Schedule 13D as specifically set forth herein. Capitalized terms used herein and not otherwise defined in this Amendment No. 2 have the meanings set forth in the Schedule 13D. This Amendment No. 2 amends Items 3, 4 and 5(a)-(c) as set forth below.

     

    Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
       
     

    Item 3 of the Schedule 13D is hereby amended and restated as follows:

     

    The securities reported herein were purchased with working capital of the Master Fund in open market purchases, except as indicated otherwise in this Schedule 13D.

     

    The aggregate purchase price of the 116,820,452 Ordinary Shares (represented by 16,688,636 ADSs) reported herein is $122,193,074.92.

       
    Item 4. PURPOSE OF TRANSACTION.
       
     

    Item 4 of the Schedule 13D is hereby amended and supplemented as follows:

     

    On June 27, 2023, the transactions contemplated by the Purchase Agreement (as described in Amendment No. 1 to the Schedule 13D filed on May 25, 2023) closed.

       
    Item 5. INTEREST IN SECURITIES OF THE ISSUER.
       
      Items 5(a)-(c) of the Schedule 13D are hereby amended and restated as follows:
       
    (a) The percentages used in this Schedule 13D are calculated based upon 424,294,455 Ordinary Shares outstanding which is the sum of (i) 386,606,014 Ordinary Shares outstanding as of May 8, 2023, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, filed with the Securities and Exchange Commission on May 11, 2023 and (ii) 37,688,441 Ordinary Shares represented by the ADS issued pursuant to the Purchase Agreement.
       
      See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number and percentage of the Ordinary Shares beneficially owned by each of the Reporting Persons. The filing of this Schedule 13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer that he or it does not directly own.
       

      

     

     

    CUSIP No. 02290A102SCHEDULE 13DPage 7 of 8 Pages

     

       
    (b) See rows (7) through (10) of the cover pages to this Schedule 13D for the number of Ordinary Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
       
    (c) Other than as set forth in Item 4, no transactions in the ADSs or Ordinary Shares have been effected by any Reporting Person during the past sixty (60) days.  

     

     

     

     

    CUSIP No. 02290A102SCHEDULE 13DPage 8 of 8 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: June 28, 2023

     

     

    DARWIN GLOBAL MANAGEMENT, LTD.  
       
    /s/ John Legge  
    Name: John Legge  
    Title: Director and Chief Financial Officer  
       
       
    /s/ Dr. Abhishek Trehan  
    DR. ABHISHEK TREHAN  

     

     

     
    DARWIN GLOBAL Master fund, LTD.  

     

    By: DARWIN GLOBAL MANAGEMENT, LTD, its investment manager

     
       
    /s/ John Legge  
    Name: John Legge  
    Title: Director and Chief Financial Officer  

     

    Get the next $AMAM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMAM

    DatePrice TargetRatingAnalyst
    9/25/2023$15.00Mkt Outperform
    JMP Securities
    9/12/2023$26.00Buy
    BTIG Research
    7/31/2023$29.00Outperform
    RBC Capital Mkts
    6/14/2023$26.00Buy
    B. Riley Securities
    6/2/2023$30.00Outperform
    Oppenheimer
    5/19/2023$25.00Overweight
    Cantor Fitzgerald
    4/7/2022$16.00Outperform
    Robert W. Baird
    2/28/2022$6.00Neutral
    Goldman Sachs
    More analyst ratings

    $AMAM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

      – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

      10/29/24 8:00:00 AM ET
      $AMAM
      $KURA
      $RNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ambrx Shareholders Approve Acquisition by Johnson & Johnson

      SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., ("Ambrx" or the "Company") (NASDAQ:AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders. As previously announced, under the terms of the transaction, Ambrx shareholders will receive $28.00 per share in cash in connection with the closing of the transaction. Daniel J. O'Connor, Chief Executive Officer of Ambrx, said, "We want to thank our shareholders for their strong support of this transaction. With a steadfast focus on protein engineering innovation and some of the best ADC talent in t

      3/6/24 1:20:00 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Announces Sale to Johnson & Johnson

      SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ:AMAM), today announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for $28.00 per share in cash, representing an approximately 105% premium to Ambrx's closing stock price on January 5, 2024, for a total equity value of approximately $2.0 billion. "We are excited to reach this agreement with Johnson & Johnson for advancing scientific research to treat cancers with high unmet needs," said Daniel J. O'Connor, Chief Executive Officer of Ambrx. "With our deep and unique knowledge of precision engineering of protein ther

      1/8/24 7:35:00 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JMP Securities initiated coverage on Ambrx Biopharma with a new price target

      JMP Securities initiated coverage of Ambrx Biopharma with a rating of Mkt Outperform and set a new price target of $15.00

      9/25/23 7:12:57 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BTIG Research initiated coverage on Ambrx Biopharma with a new price target

      BTIG Research initiated coverage of Ambrx Biopharma with a rating of Buy and set a new price target of $26.00

      9/12/23 7:13:06 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • RBC Capital Mkts initiated coverage on Ambrx Biopharma with a new price target

      RBC Capital Mkts initiated coverage of Ambrx Biopharma with a rating of Outperform and set a new price target of $29.00

      7/31/23 7:17:15 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    SEC Filings

    See more
    • SEC Form 15-12G filed by Ambrx Biopharma Inc.

      15-12G - Ambrx Biopharma, Inc. (0001990550) (Filer)

      3/18/24 2:45:48 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Biopharma Inc. filed SEC Form 8-K: Leadership Update

      8-K - Ambrx Biopharma, Inc. (0001990550) (Filer)

      3/12/24 4:55:02 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Ambrx Biopharma Inc.

      EFFECT - Ambrx Biopharma, Inc. (0001990550) (Filer)

      3/11/24 12:15:20 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Financials

    Live finance-specific insights

    See more
    • Ambrx to Commence Trading on Nasdaq

      Company to Transfer Stock Exchange Listing from NYSE to Nasdaq Ticker symbol will remain "AMAM" Ambrx Biopharma Inc. (NYSE: AMAM) ("Ambrx" or "the Company") today announced that it will voluntarily transfer its stock exchange listing to the Nasdaq Stock Market from the New York Stock Exchange, effective March 16, 2023 after market close. Ambrx's American Depositary Shares are expected to begin trading as a Nasdaq-listed security on March 17, 2023. The Company will retain its current ticker symbol "AMAM". "The listing of our stock on the Nasdaq represents a significant milestone in our growth as a publicly-traded company and is an important step that will help facilitate our mission to di

      3/6/23 9:00:00 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Biopharma Inc. Announces Strategic Reprioritization and Provides Corporate Update

      - Company now focused on earlier stage engineered antibody drugs for cancer therapies, including new lead asset ARX517 – - Revised focus and projected cost-reductions expected to extend cash runway into 2025 – - Ambrx to host a conference call today at 5:00 p.m. EST / 2:00 p.m. PST - SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE:AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced a strategic reprioritization of its pipeline and provided a corporate update. The strategic assessment considered the company's cash runway, pipeline near term v

      10/18/22 4:05:00 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Biopharma to Host Corporate Update Conference Call

      SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE:AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the company will host a corporate update conference call and live webcast on October 18, 2022 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time, to discuss the company's strategic review of its development pipeline. Individuals interested in listening to the conference call may do so by registering via the webcast link in the investor relations section of the company's website at: www.ambrx.com. To access the call by phone, please use the reg

      10/11/22 4:05:00 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Hermans Kate

      4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)

      3/7/24 7:23:35 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Loesberg Janet

      4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)

      3/7/24 7:19:43 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • O'Connor Daniel J. returned 48,202 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)

      3/7/24 5:46:49 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Ambrx Biopharma Inc. (Amendment)

      SC 13G/A - Ambrx Biopharma Cayman, Inc. (0001836056) (Subject)

      2/9/24 5:08:30 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Ambrx Biopharma Inc.

      SC 13G - Ambrx Biopharma Inc. (0001836056) (Subject)

      10/10/23 11:35:22 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Ambrx Biopharma Inc.

      SC 13G - Ambrx Biopharma Inc. (0001836056) (Subject)

      9/25/23 5:24:50 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Leadership Updates

    Live Leadership Updates

    See more
    • Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

      – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

      10/29/24 8:00:00 AM ET
      $AMAM
      $KURA
      $RNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ambrx Appoints Renu Vaish, M.Sc., as Chief Regulatory Officer to Lead Regulatory Affairs

      SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc. ("Ambrx" or the "Company") (NASDAQ:AMAM), today announced the appointment of Renu Vaish, M.Sc., as Chief Regulatory Officer. Ms. Vaish will be responsible for overseeing and designing the Company's global regulatory strategy and will report to the Company's President and Chief Executive Officer, Daniel J. O'Connor. Ms. Vaish is an experienced leader in U.S. and global regulatory affairs with extensive experience in oncology drug development ranging from pre-clinical to commercial products in many fields, including prostate and breast cancer. She has held senior regulatory leadership positions at Celgene, Merck and Kite Phar

      8/1/23 8:30:00 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Appoints Jared Kelly as General Counsel

      SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ:AMAM), today announced the appointment of Jared Kelly as Senior Vice President, General Counsel and Corporate Secretary. After practicing for more than ten years at large corporate law firms, Mr. Kelly brings his extensive experience advising public companies on corporate governance, financing transactions and mergers and acquisitions to Ambrx. He will be responsible for developing and overseeing the legal strategy of the Company and for providing legal guidance to the Company's board of directors, executive management team and other business units. Mr. Kelly is an experienced public company lawyer who

      6/5/23 8:30:00 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Cormorant Asset Management, Lp bought $19,625,601 worth of Ordinary Shares (2,152,738 units at $9.12)

      4 - Ambrx Biopharma Inc. (0001836056) (Issuer)

      9/19/23 4:49:06 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care